Including Atrial Fibrillation as Chronic Condition under Chronic Disease Management Programme for use of MediSave
14 February 2022
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
NOTICE PAPER NO. 949
NOTICE OF QUESTION FOR WRITTEN ANSWER
FOR THE SITTING OF PARLIAMENT ON 14 FEBRUARY 2022
Name and Constituency of Member of Parliament
Mr Patrick Tay Teck Guan
MP for Pioneer
Question No. 1506
To ask the Minister for Health whether the Ministry will consider including atrial fibrillation as a chronic condition under the Chronic Disease Management Programme for MediSave to be utilised for drugs such as apixaban for treating this condition.
Written Answer
Patients diagnosed with atrial fibrillation arising from a condition under the Chronic Disease Management Programme (CDMP), such as hypertension, can use MediSave for their treatment, including medications such as apixaban. However, atrial fibrillation as a stand-alone condition is currently not under the CDMP.
CDMP conditions are regularly reviewed in consultation with the CDMP Clinical Advisory Committee (CAC), and based on considerations such as disease burden, effectiveness of early intervention to reduce complications, and availability of clear clinical treatment guidelines. We will take atrial fibrillation into account in our next review.